Will Angiotensin II receptor blockers (ARBs) be the future in hypertensive treatment?

This press release highlight future changes in the treatment of hypertension. You will be updated on new anti-hypertensive drug combinations and learn more about the future market development.

(PRWEB) September 25, 2004 -- BioMarket Group announces the addition of a new report entitled "Pipeline Insight: Antihypertensives - Together We Stand, Divided We Fail.

This unique business intelligence report, published by Datamonitor has been released. Ongoing large-scale clinical trials with ARBs are resulting in a shift in physician preference from ACE inhibitors to ARBs and many believe we have reached a significant turning point in the future of ACE inhibitors. Moreover, this analysis also indicates that the future will bring combination therapies into focus. One example is Aliskiren, this drug will be the first oral renin inhibitor to be launched. Its intervention at an earlier stage in the Renin Angiotensin System means it may offer significant advantages in efficacy and tolerability over both ARBs and ACE inhibitors and is likely to become a new blockbuster.

Datamonitor believes that fixed dose combination therapy will grow substantially over the forecast period, exceeding the growth of single pills. Successful strategies for controlling hypertension will need to merge fixed dose combination options with patient-led therapeutic regimes.

Read this report in order to:

- View independent sales forecasts for products in late stage development for treatment of hypertension in both existing and novel classes

- Understand physicians' views on ARBs as the potential future gold standard class and the threats faced by existing and developmental products

- Identify early stage antihypertensive compounds with high potential being developed by companies seeking a marketing partner

About BioMarket Group:

BioMarket Group is an aggregator of global business intelligence in the biotech and life science industry. Companies turn to BMG for in-depth industry research, global business information and independent equity analysis. Gain easy access to reports, newsletters, company profiles and more through www.biomarketgroup.com. By continuously updating research from over 100 of the leading research firms and consultancies worldwide, BMG provides the most relevant, current and credible research available. Our Research Specialists bring an unbiased approach to identifying the information business professionals need to make effective strategic decisions.

###